Katrina Birdwell, MD
Surgical Oncology · Dallas, TXNPI 1508067760
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 8.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $285, more than ten times the $11 reported in 2019. That places this record below the midpoint for surgical oncology clinicians in TX, where the typical reported total is $1,562.
Across 34 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$59
- Regeneron Healthcare Solutions, Inc.$49
- Johnson & Johnson$41
- Takeda Pharmaceuticals U.S.A., Inc.$36
- AbbVie$35
- Davol Inc.$34
- plus $425 from 21 others
What the payments were for
- Food & beverage$678100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Johnson & Johnson(2 entities) | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| AbbVie(2 entities) | 2 | $35 |
| Davol Inc. | 1 | $34 |
| Endomagnetics Ltd | 1 | $27 |
| Sobi, Inc | 1 | $27 |
| Bayer | 1 | $26 |
| Boston Scientific | 1 | $26 |
| Mirati Therapeutics, Inc. | 1 | $25 |
| Kerecis Limited | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Pfizer | 1 | $23 |
| Solventum Corporation | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $21 |
| Caris MPI, Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Immunogen, Inc. | 1 | $19 |
| Seagen Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
| Pharmaand GmbH | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
| Bioptics, Inc. | 1 | $12 |
| Sirius Medical Systems | 1 | $10 |
How this compares
$678 in reported general payments places this provider in the 35th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tramadol Hcl | 50 | $135 |
| Gabapentin | 19 | $54 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Dallas
- Allison DipasqualeDallas$272K
- Adam YoppDallas$96K
- Peter BeitschDallas$62K
- Patricio PolancoDallas$61K
- William McNamaraDallas$16K
- Glen BalchDallas$11K
- Michael ChotiDallas$6K
- Deborah FarrDallas$4K
- David KangDallas$4K
- Merrick RossHouston$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.